Pharma major Mylan gets go-ahead to make remdesivir for 'restricted emergency use'

Written informed consent of each patient is required before the use of
the drug while active post-marketing surveillance data and reporting
of serious adverse events have to be submitted. On June 21, Hetero and
Cipla were given permission to manufacture and market the drug on the
same conditions.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pharma-major-mylan-gets-go-ahead-to-make-remdesivir-for-restricted-emergency-use/articleshow/76750791.cms